COSM

Highest Q2 and H1 revenue in Company history, reflecting strength across all core segments and reaching a new milestone with an adjusted annualized revenue run-rate exceeding $75 million Continued progress toward profitability targets, with adjusted gross profit reaching approximately $7.4 million on an annualized basis, adjusted gross margin expanding 165 basis points to 9.54%, and adjusted EBITDA improving 13.8% Demonstrated operating leverage and disciplined inventory management, with Q2 operating expenses growing at roughly half the rate of revenue and first-half inventory down 21.8% despite nearly 30% revenue growth Strengthened balance sheet, with total liabilities decreasing 13.3% by $6.27 million, stockholders' equity rising 12.2% to $20.67 million, and the liabilities-to-assets ratio improving by 550 basis points Liquid assets of $4.15 million, comprising cash, marketable securities and digital assets Share repurchase program actively underway as record momentum continues into Q3 2026 CHICAGO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today reported financial results for the second quarter and six months ended June 30, 2026. Second Quarter and First Half 2026 Financial Highlights Income Statement Cosmos Health delivered its highest second-quarter and first-half revenue in Company history, with growth contributed by every core division. Decahedron nearly doubled its revenue in the United Kingdom, Cana Laboratories built its contract manufacturing orderbook to an all-time high of over 25 million units, CosmoFarm added more than 75 new pharmacies to its distribution network, and the Company's proprietary brands — including Sky Premium Life, C-Sept and C-Scrub — continued their international expansion. Revenue was $18.99 million in Q2 2026, an increase of 28.8% from $14.75 million in Q2 2025, and $36.91 million for the first half, up 29.7% from $28.46 million in the prior-year period, driven by higher sales volumes across all core segments. Gross profit was $1.51 million in Q2 2026, an increase of 29.9% from $1.16 million in Q2 2025, broadly in line with revenue growth. For the first half, gross profit was $2.89 million compared to $3.21 million in the prior-year period, primarily reflecting $0.80 million of sales discount reversals with no corresponding reduction in cost of goods sold. Gross margin was 7.96% in Q2 2026, compared to 7.89% in Q2 2025, and 7.84% for the first half, compared to 11.29% in the prior-year period, with the first-half decline reflecting the same reversals. Total operating expenses were $4.44 million in Q2 2026, an increase of 16.5% from $3.81 million in Q2 2025, and $8.00 million for the first half, up 19.6% from $6.69 million in the prior-year period — in both periods growing well below revenue, which rose 28.8% and 29.7%, respectively. Net income (loss) was ($6.09 million) in Q2 2026, compared to ($2.83 million) in Q2 2025, and ($8.89 million) for the first half, compared to ($3.65 million) in the prior-year period, primarily reflecting $2.65 million of non-cash charges in the quarter, principally related to fair value adjustments on the Company's financing arrangements. Balance Sheet Cosmos Health strengthened its capital structure during the first half of 2026, reducing total liabilities for a second consecutive quarter while lifting stockholders' equity and improving working capital efficiency, with receivables and inventory both declining against nearly 30% revenue growth on improved collections and more disciplined inventory management. Total liabilities decreased by $6.27 million, or 13.3%, to $40.79 million as of June 30, 2026, from $47.05 million at year-end 2025. Total assets were $61.46 million as of June 30, 2026, compared to $65.48 million at year-end 2025. The asset base remains diversified, including a solid real estate and intellectual property portfolio. Total stockholders' equity increased by $2.25 million, or 12.2%, to $20.67 million from $18.42 million at December 31, 2025, while the liabilities-to-assets ratio improved by 550 basis points to 66.4% from 71.9%. Share Repurchase Program On June 26, 2026, the Company's Board of Directors authorized a share repurchase program of up to $5.0 million, expiring December 31, 2026 and renewable at the Company's sole discretion. Cosmos Health repurchased 2,650,000 shares for approximately $513,000 during the second quarter, and open market purchases have continued into Q3 2026, bringing total repurchases as of this date to 5,112,000 shares for approximately $1.11 million. Q2 2026 Business Highlights Commercial Expansion CosmoFarm delivered record quarterly revenue of over $15 million, a $60+ million annualized run-rate, adding over 75 new pharmacies Achieved pan-European distribution for Sky Premium Life through Skroutz, making products available across all 27 EU Member States Signed a distribution agreement with International Medical Company for Qatar, whose Kulud Pharmacies arm is the country's largest chain, securing an initial order of 31,000 Sky Premium Life units Received a third consecutive order from Pharmalink in the UAE for 60,000 Sky Premium Life units, taking cumulative orders to 270,000 United States Expansion Introduced the "18 Series," a science-driven nutraceutical platform targeting a portfolio of 18 products. Initial focus areas include liver health, joint and inflammation support, cardiovascular health, men's wellness and healthy aging Entered the $163 billion global skincare market, with U.S. sales already underway Contract Manufacturing Cana Laboratories built its orderbook to an all-time high of over 25 million units across nine therapeutic categories, under agreements extending up to ten years Signed a 3.9 million-unit agreement with Verisfield for VASCLOR GEST progesterone pessaries Signed a 2.86 million-unit agreement with Pharmex S.A. across three dermatological products Received further orders from Nassington and Verisfield totalling 253,657 units across a range of medicines Inaugurated a new capsule production line alongside a five-year agreement with Provident Pharmaceuticals for 385,000 units of CERTORUN Clinical Validation and New Categories C-Scrub Wash 4% successfully completed testing under EN 12791, the European standard for surgical hand disinfection, supporting entry into hospital, surgical and professional healthcare channels C-Sept PRO gained traction across leading Greek public and private hospital groups Reported annualized sales above $1.5 million for C-Scrub and C-Sept in the UK and Greece, with planned EU expansion targeting $7.4 million in revenue and $5.3 million in gross profit Entered the $69 billion global animal health industry with a veterinary formulation of C-Scrub Wash 4%, following successful testing under EN 1656 and EN 1657 R&D and Innovation Consolidated full ownership of the CCX0722 weight-management hydrogel patent and advanced the international application into the United States, Europe, Australia and Canada Expanded AI integration across order management, warehouse and supply chain operations, with the potential to reduce certain operating expenses by up to 30% Corporate and Capital Structure Entered into an advisory agreement through Cana Laboratories with the European Investment Bank (EIB) for the financing of its R&D programme, under which EIB financing could represent up to €25 million Identified approximately $20 million in non-core assets available for monetization to accelerate growth Signed a letter of intent to acquire Doc Pharma S.A., an affiliated European GMP pharmaceutical manufacturer 4,874,126 Series B warrants expired unexercised, eliminating approximately 38% of total warrant overhang with no dilution Board authorized a share repurchase program of up to $5.0 million Management Commentary Greg Siokas, CEO of Cosmos Health, stated: "Q2 2026 was a record second quarter, with revenue of $18.99 million, up 29% year-over-year, capping a record first half of $36.91 million. On an adjusted basis, this represents an annualized revenue run-rate in excess of $75 million — a new milestone for Cosmos, and one achieved before any impact from potential acquisitions or from second-half seasonality, which was materially stronger last year and which we expect again this year. Every core division contributed: CosmoFarm added over 75 pharmacies, Cana built its contract manufacturing orderbook to over 25 million units, and Decahedron nearly doubled its revenue in the United Kingdom. Our proprietary brands continued to gain ground. Sky Premium Life extended its reach across Europe and the UAE through new distribution agreements. C-Scrub and C-Sept continued to build momentum, with C-Sept PRO gaining traction across leading Greek hospital groups, and C-Scrub cleared EN 12791 for surgical hand disinfection — opening the hospital and surgical channels as well as an entirely new vertical for us in animal health. During the quarter we also took our U.S. expansion from concept to execution with the 18 Series, a portfolio we are building toward 18 clinically validated products spanning liver health, joint and inflammation support, cardiovascular health, men's wellness and healthy aging, among other areas. Supported by local manufacturing, we expect the United States to become one of our principal growth engines. Equally important is how we achieved this growth. Adjusted gross profit rose 58% in the quarter with adjusted gross margin expanding 165 basis points, operating expenses grew at little more than half the rate of revenue, and we reduced both receivables and inventory while revenue grew nearly 30%. That is the operating leverage we have been building toward, and we are investing to extend it — a new capsule production line at Cana, robotic automation and AI systems at CosmoFarm, and AI integration across order management, warehousing and supply chain, where we see scope to reduce certain operating expenses further. We also cut total liabilities by $6.3 million since year-end, lifting stockholders' equity 12% to $20.7 million and improving our liabilities-to-assets ratio by 550 basis points. Separately, we began buying back our own stock because we believe our shares trade well below the underlying value of our diversified asset base and growth prospects. Moving forward, we are starting to see the benefits of economies of scale and vertical integration, and we expect increased efficiencies to play an important role as we progress toward sustained profitability. That momentum carries into Q3 2026 across every core segment, with our U.S. platform beginning to contribute." UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (*) See "Definitions of Non-GAAP Measures" and "Reconciliation of Non-GAAP Measures" sections herein for an explanation and reconciliations of non-GAAP measures used throughout this release. Definitions of Non-GAAP Measures We collect and analyze operating and financial data to evaluate the health of our business and assess our performance. In addition to Revenue, Gross Profit, Income (Loss) from Operations and Net Income (Loss) under GAAP, we use: Adjusted Revenue, Adjusted Gross Profit, EBITDA, Adjusted EBITDA, and Adjusted Net Income (Loss). We have included these non-GAAP financial measures because they are key measures used by our management to evaluate our operating performance. Accordingly, we believe that these non-GAAP financial measures provide useful information to investors and others in understanding and evaluating our operating results in the same manner as our management team and Board of Directors. Therefore, these non-GAAP financial measures are presented here. Our calculation of these non-GAAP financial measures may differ from similarly titled non-GAAP measures, if any, reported by our peer companies. These non-GAAP financial measures should not be considered in isolation from, or as substitutes for, financial information prepared in accordance with GAAP. Adjusted Revenue We define Adjusted Revenue as GAAP Revenue adjusted to include revenues subject to revenue recognition timing adjustments. Adjusted Revenue is supplemental in nature and is not meant as a substitute for Revenue prepared in accordance with GAAP. Adjusted Gross Profit We define Adjusted Gross Profit as GAAP Gross Profit adjusted for the same revenue recognition timing adjustments described under Adjusted Revenue above. Adjusted Gross Profit is supplemental in nature and is not meant as a substitute for Gross Profit prepared in accordance with GAAP. Adjusted EBITDA We define Adjusted EBITDA as Income (Loss) before Income Taxes, excluding (i) depreciation and amortization expense, (ii) interest income (expense), net, (iii) non-cash interest expense and change in fair value of convertible notes, (iv) stock-based compensation expense, (v) non-recurring and extraordinary items, (vi) other income (expense), net, (vii) gain (loss) on equity investments, net, (viii) change in fair value of derivative liability, (ix) gain (loss) on digital assets, (x) foreign currency transaction, net, and (xi) sales discount reversals. We have included Adjusted EBITDA because it is a key measure used by our management team to evaluate our operating performance, generate future operating plans, and make strategic decisions. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management team and Board of Directors. In addition, it provides a useful measure for period-to-period comparisons of our business, as it removes the effect of certain non-cash expenses and non-recurring and extraordinary items. For investors to better evaluate the Company's performance and compare results across reporting periods, Cosmos Health provides a reconciliation of GAAP to non-GAAP financial measures. These adjustments exclude certain non-cash and non-recurring items, including stock-based compensation, non-cash interest expense, changes in the fair value of derivatives and convertible notes, gains or losses on digital assets, foreign currency transactions, sales discount reversals, and other non-operating or non-recurring items, as applicable and as further described above. The presentation of the Company's non-GAAP financial measures is not meant to be considered in isolation or as a substitute for the Company's financial results prepared in accordance with GAAP, and the Company's non-GAAP measures may be different from non-GAAP measures used by other companies. Adjusted EBITDA has limitations as a financial measure, should be considered as supplemental in nature, and is not meant as a substitute for the related financial information prepared in accordance with GAAP. Adjusted Net Income (Loss) We define Adjusted Net Income (Loss) as Adjusted EBITDA (see above) adding provision for income taxes and deducting interest expense. Adjusted Net Income (Loss) has limitations as a financial measure, should be considered as supplemental in nature, and is not meant as a substitute for the related financial information prepared in accordance with GAAP. Reconciliation of Non-GAAP Measures Adjusted Revenue, Adjusted Gross Profit, Adjusted EBITDA & Adjusted Net Income (Loss) The following table presents reconciliations of Adjusted Revenue, Adjusted Gross Profit, Adjusted EBITDA and Adjusted Net Income (Loss) to the most directly comparable GAAP financial measures for each of the periods indicated. About Cosmos Health Inc. Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X. Forward-Looking Statements With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company’s business, operations, and the economy in general; the Company’s ability to successfully develop and commercialize its proprietary products and technologies; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties – many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us – as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC’s website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements. Investor Relations Contact: BDG Communications [email protected]

By Brad Sorensen, CFA NASDAQ: COSM READ THE FULL COSM RESEARCH REPORT Cosmos Health (NASDAQ: COSM) delivered a strong second-quarter update that, in our view, provides additional evidence that the company is transitioning from a collection of healthcare assets into a larger, vertically integrated healthcare platform with increasingly meaningful scale. The headline numbers were encouraging: record second-quarter and first-half revenue, significant growth in adjusted gross profit, improving adjusted EBITDA, better operating leverage, a stronger balance sheet, and continued share repurchases. Perhaps more important for longer-term investors, several of Cosmos Health's growth initiatives—including CosmoFarm, Cana Laboratories, proprietary nutraceuticals, international distribution and the company's developing U.S. business—are beginning to contribute simultaneously. Cosmos Health is a diversified healthcare company with operations spanning pharmaceutical distribution, manufacturing, proprietary nutraceutical and pharmaceutical brands, healthcare products, and research and development. Its vertically integrated structure differentiates it from a traditional pharmaceutical distributor. The company owns brands including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through Cana Laboratories, Cosmos operates an EU-GMP pharmaceutical manufacturing business capable of producing pharmaceuticals, supplements, cosmetics, biocides and medical devices. Meanwhile, CosmoFarm provides pharmaceutical distribution in Greece, and Decahedron serves the UK market. Record Q2 Results Demonstrate Accelerating Scale We believe the most important takeaway from the Q2 release is the strength of revenue growth. Second-quarter revenue reached a record $18.99 million, up 28.8% from $14.75 million a year ago. First-half revenue increased 29.7% to $36.91 million from $28.46 million. Adjusting for certain sales discount reversals, Q2 revenue was $19.32 million, up 31%, while first-half adjusted revenue reached $37.72 million, up 32.5%. Management noted that this represents an adjusted annualized revenue run rate exceeding $75 million. We see this as an important milestone because Cosmos generated only $65.3 million of revenue during all of 2025. The current run rate suggests to us that the company's growth trajectory has moved meaningfully higher even before incorporating potential acquisitions and the historically stronger seasonality management expects during the second half. The quality of the Q2 growth also appears to be improving. Reported gross profit increased 29.9% to $1.51 million, roughly matching revenue growth. More impressively, adjusted gross profit increased 58.4% to $1.84 million, while adjusted gross margin expanded 165 basis points to 9.54%. This margin expansion is particularly significant to the COSM investment case. Cosmos has historically generated a substantial portion of revenue from relatively low-margin pharmaceutical distribution. As higher-margin proprietary products, contract manufacturing, and specialized healthcare products become larger contributors, there is an opportunity for gross profit to grow materially faster than revenue. Q2 provides some early evidence of that progression. Operating Leverage Is Beginning to Emerge Another very encouraging feature of the quarter to us was the expense control relative to growth. Operating expenses increased 16.5% to $4.44 million while revenue grew 28.8%. Salaries and wages actually declined 0.7% year over year despite the substantial increase in revenue. Management also reported that receivables and inventory declined even as sales approached 30% growth; first-half inventory was down 21.8%. These figures suggest that Cosmos is beginning to generate operating leverage. Revenue is growing considerably faster than the expense base, while inventory management and collections are becoming more efficient. This dynamic could become increasingly important as revenue scales because a greater portion of incremental gross profit could ultimately flow through to EBITDA. Adjusted EBITDA provides another encouraging indicator. The Q2 adjusted EBITDA loss improved to $1.13 million from a loss of $1.31 million a year earlier despite continued investment in international expansion and proprietary brands. The reported net loss of $6.09 million appears much less favorable, compared with a $2.83 million loss a year ago. However, approximately $2.65 million of the quarterly loss reflected non-cash charges, principally fair-value adjustments associated with financing arrangements and not as a result of core operations. CosmoFarm Is Becoming a Significant Revenue Engine Within the COSM universe, CosmoFarm continues to be one of the largest drivers of growth. The business generated more than $15 million of quarterly revenue during Q2, equivalent to an annualized run rate exceeding $60 million, while adding more than 75 pharmacies to its distribution network. Cosmos is also investing in robotic automation and AI technology at CosmoFarm. Combined with the company's broader AI initiatives in inventory, warehousing, procurement, and order management, management believes technology could reduce certain operating expenses by as much as 30%. We believe CosmoFarm provides a large and expanding revenue base and pharmacy distribution infrastructure, while automation potentially creates an avenue for better margins as volume increases. Cana Laboratories Provides Growing Visibility While CosmoFarm growth is impressive, Cana Laboratories may ultimately prove even more important from a profitability standpoint. Its contract manufacturing orderbook has reached an all-time high exceeding 25 million units across nine therapeutic categories, with agreements extending for periods of up to ten years. Recent agreements include a 3.9-million-unit contract with Verisfield for VASCLOR GEST progesterone pessaries and a 2.86-million-unit agreement with Pharmex covering three dermatological products. Additional orders from Nassington and Verisfield totaled more than 253,000 units, while Cosmos inaugurated a new capsule manufacturing line accompanied by a five-year agreement with Provident Pharmaceuticals for 385,000 units of CERTORUN. This expanding orderbook is attractive because it provides Cosmos with greater revenue visibility than ordinary pharmaceutical distribution. Long-duration manufacturing agreements can also improve utilization of Cana's production infrastructure, potentially increasing margins as manufacturing volumes rise. Additionally, Cana entered an advisory agreement with the European Investment Bank regarding potential financing of Cosmos' R&D program. The company indicated that EIB financing could total as much as €25 million. We don’t believe this should be viewed as committed financing at this stage, but successful completion could provide a significant source of capital for R&D without relying entirely on conventional equity funding. Proprietary Products Could Change the Margin Profile Cosmos continues to expand its higher-margin proprietary brands internationally. Sky Premium Life achieved pan-European distribution through Skroutz, making its products available across all 27 EU member states. The company also signed a distribution agreement with International Medical Company in Qatar, including an initial order for 31,000 Sky Premium Life units, and received another 60,000-unit order from Pharmalink in the UAE, bringing cumulative orders from that relationship to 270,000 units. C-Scrub and C-Sept are also becoming increasingly meaningful. Combined annualized sales have exceeded $1.5 million in Greece and the UK. Cosmos believes planned European expansion could ultimately generate approximately $7.4 million in revenue and $5.3 million in gross profit—an implied margin dramatically above the company's consolidated margin today. Another recent product, C-Scrub Wash 4%, successfully completed EN 12791 testing, the European standard covering surgical hand disinfection. That potentially opens hospital, surgical, and professional healthcare markets. Separately, successful EN 1656 and EN 1657 testing has allowed Cosmos to target the approximately $69 billion global animal-health market with a veterinary formulation of C-Scrub Wash 4%. These developments demonstrate to us why proprietary products matter so much to the long-term COSM story. Distribution establishes scale, but proprietary products potentially provide the margins capable of transforming the company's earnings profile. The U.S. Opportunity Adds Another Growth Driver We see the company's U.S. expansion as another potentially important catalyst. During Q2, Cosmos moved its "18 Series" from concept toward commercialization. The platform is intended to eventually contain 18 clinically validated nutraceutical products addressing areas including liver health, joint and inflammation support, cardiovascular health, men's wellness and healthy aging. Cosmos also entered the global skincare market, which the company estimates at approximately $163 billion, with U.S. sales already underway. The attraction of the U.S. strategy is not simply additional revenue. Proprietary nutraceutical and skincare products have the potential to generate substantially higher margins than pharmaceutical wholesaling. Management has described the United States as a prospective principal growth engine, supported by local manufacturing. Balance Sheet Improvement Is an Underappreciated Positive The Q2 release also contained meaningful balance-sheet progress. Total liabilities declined $6.27 million, or 13.3%, from year-end to $40.79 million. At the same time, stockholders' equity increased $2.25 million, or 12.2%, to $20.67 million. The liabilities-to-assets ratio improved by 550 basis points, from 71.9% to 66.4%. Cosmos reported $4.15 million of liquid assets consisting of cash, marketable securities, and digital assets. Management has additionally identified approximately $20 million of non-core assets that potentially could be monetized to fund growth or improve the capital structure. The company also signed an LOI to acquire Doc Pharma S.A., an affiliated European GMP pharmaceutical manufacturer. Management's actions regarding the stock are also encouraging to us. Cosmos authorized a share repurchase program of up to $5 million in June. It repurchased 2.65 million shares for approximately $513,000 during Q2, and purchases continued during Q3. As of today's announcement, Cosmos had repurchased approximately 5.112 million shares for roughly $1.11 million. At the same time, approximately 4.87 million Series B warrants expired unexercised during the quarter, eliminating roughly 38% of the company's warrant overhang without additional dilution. For shareholders, the combination of reduced warrant overhang and active open-market repurchases should be encouraging to further increase the value of remaining shares. Longer-Term Outlook The most compelling element of the COSM story to us is the changing composition of the business. Cosmos increasingly combines the scale of pharmaceutical distribution, the recurring potential of contract manufacturing, the higher margins of proprietary healthcare products, international expansion, U.S. nutraceutical opportunities and an emerging R&D portfolio. Q2 2026 provides evidence that this strategy is gaining traction. Revenue increased nearly 29%, adjusted gross profit increased 58%, adjusted gross margin expanded 165 basis points, operating expenses grew considerably more slowly than revenue, adjusted EBITDA improved, liabilities declined 13%, equity increased 12%, and management continued buying back shares. At the operating level, CosmoFarm surpassed a $60 million annualized revenue pace, Cana's manufacturing orderbook exceeded 25 million units, international orders for Sky Premium Life continued to expand, and C-Scrub and C-Sept moved into potentially valuable new markets. COSM remains a higher-risk small-cap investment, and those risks should not be minimized. However, today's Q2 report strengthens our positive investment view: Cosmos is considerably larger than it was a year ago, its adjusted profitability metrics are improving, its balance sheet is moving in the right direction, and several potentially high-margin businesses remain at relatively early stages of commercialization. For investors willing to accept the risks associated with a small-cap healthcare company, the combination of nearly 30% first-half revenue growth, improving operating leverage, a growing manufacturing backlog, international expansion, a developing U.S. platform, proprietary products, and management's willingness to repurchase shares creates a potentially attractive setup. SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.

Record Q1 revenue of $17.9M, up 31% from $13.71 million in Q1 2025, reflecting strength across all core segments Total liabilities decreased by $4.5M, or 9.6%, driven by a substantial reduction in convertible note and credit facility balances Stockholders' equity increased by $1.4M, or 7.6%, with the liabilities-to-assets ratio improving by 370 basis points Adjusted EBITDA near breakeven as increased revenue was offset by strategic investments to support global growth Record momentum continues into Q2 2026 with U.S. expansion actively underway CHICAGO, IL / ACCESS Newswire / May 21, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights Income Statement Cosmos Health delivered the highest Q1 revenue in Company history with continued progress toward adjusted profitability, reflecting broad-based commercial strength - over 75 new pharmacies added at CosmoFarm, growing Sky Premium Life order activity across multiple markets, and expanded contract manufacturing agreements at Cana Laboratories. Revenue was $17.93 million, an increase of 30.7% from $13.71 million in Q1 2025, reflecting strong sales momentum across all core divisions. Gross profit was $1.38 million in Q1 2026, compared to $2.05 million in Q1 2025, reflecting a revenue mix shift toward wholesale distribution activity at CosmoFarm, compounded by the aforementioned sales discount adjustment. Total operating expenses increased to $3.57 million in Q1 2026, compared to $2.88 million in Q1 2025, reflecting strategic investments in personnel, infrastructure, technology, and AI-driven efficiencies to support global growth initiatives. Net income (loss) was ($2.81 million) in Q1 2026, compared to ($0.82 million) in Q1 2025. The increase is driven principally by $1.15 million of non-cash, non-operational items: Adjusted EBITDA was ($229,596) in Q1 2026, near breakeven, as increased revenue was offset by higher expenses reflecting the Company's ongoing investments in global growth initiatives. Adjusted Net Income (Loss) was ($996,502), driven by $766,906 in interest expense incurred in support of the Company's growth investments. Balance Sheet Cosmos Health continued to improve its balance sheet in Q1 2026, with active debt reduction and working capital optimization driving an improvement in the liabilities-to-assets ratio to 68.2% from 71.9% at year-end 2025. Total assets were $62.37 million as of March 31, 2026, compared to $65.48 million at December 31, 2025, reflecting a diversified asset base with solid liquidity, a strong inventory position, and a significant real estate and intellectual property portfolio. Total liabilities decreased by $4.51 million, or 9.6%, to $42.54 million as of March 31, 2026, from $47.05 million at December 31, 2025, driven by a substantial reduction in convertible note and credit facility balances. Total stockholders' equity increased by $1.40 million, or 7.6%, to $19.83 million as of March 31, 2026, up from $18.42 million at December 31, 2025. Management Commentary Greg Siokas, CEO of Cosmos Health, stated: "Q1 2026 was a record Q1 for Cosmos Health, with revenue of $17.93 million, up 31% year-over-year and 34% on an adjusted basis, reflecting broad-based commercial momentum across every major division - record distribution volumes at CosmoFarm, continued global expansion of Sky Premium Life, and new contract manufacturing agreements at Cana Laboratories. This momentum is continuing into Q2 2026, and we are focused on sustaining it well beyond this year. We believe Cosmos Health is entering a new phase of growth, driven by strategic investments across our organization - in personnel, facilities, infrastructure, technology, and AI-driven efficiencies - to support our global expansion plans, strengthen our R&D pipeline, and build the foundation for long-term sustainable value creation. A key pillar of this growth is our entry into the lucrative U.S. nutraceuticals market through the 18 Series platform. Adjusted EBITDA is near breakeven, and we expect it to turn positive as our growth investments drive meaningful returns and revenues continue to scale. At the same time, we have been disciplined in managing our balance sheet. We reduced total liabilities by $4.5 million in a single quarter, a 9.6% reduction, driven by a substantial reduction in convertible note and credit facility balances. Meanwhile, stockholders' equity increased by 7.6%, our liabilities-to-assets ratio improved by 370 basis points, and our liquidity position remains solid, with $4.3 million in liquid assets including cash of $2.2 million, to support our growth plans. Q1 2026 is an early indication of what we believe will be a period of significant growth for Cosmos Health, and we look forward to updating our shareholders as this story continues to unfold." UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (*) See "Definitions of Non-GAAP Measures" and "Reconciliation of Non-GAAP Measures" sections herein for an explanation and reconciliations of non-GAAP measures used throughout this release. Definitions of Non-GAAP Measures We collect and analyze operating and financial data to evaluate the health of our business and assess our performance. In addition to Revenue, Gross Profit, Income (Loss) from Operations and Net Income (Loss) under GAAP, we use: Adjusted Revenue, Adjusted Gross Profit, EBITDA, Adjusted EBITDA, and Adjusted Net Income (Loss). We have included these non-GAAP financial measures because they are key measures used by our management to evaluate our operating performance. Accordingly, we believe that these non-GAAP financial measures provide useful information to investors and others in understanding and evaluating our operating results in the same manner as our management team and Board of Directors. Therefore, these non-GAAP financial measures are presented here. Our calculation of these non-GAAP financial measures may differ from similarly titled non-GAAP measures, if any, reported by our peer companies. These non-GAAP financial measures should not be considered in isolation from, or as substitutes for, financial information prepared in accordance with GAAP. Adjusted Revenue We define Adjusted Revenue as GAAP Revenue adjusted to include revenues subject to revenue recognition timing adjustments. Adjusted Revenue is supplemental in nature and is not meant as a substitute for Revenue prepared in accordance with GAAP. Adjusted Gross Profit We define Adjusted Gross Profit as GAAP Gross Profit adjusted for the same revenue recognition timing adjustments described under Adjusted Revenue above. Adjusted Gross Profit is supplemental in nature and is not meant as a substitute for Gross Profit prepared in accordance with GAAP. Adjusted EBITDA We define Adjusted EBITDA as Income (Loss) before Income Taxes, excluding (i) depreciation and amortization expense, (ii) interest income (expense), net, (iii) non-cash interest expense, (iv) stock-based compensation expense, (v) non-recurring and extraordinary items, (vi) other income (expense), net, (vii) gain (loss) on equity investments and digital assets, net, (viii) change in fair value of derivative liability and convertible notes, (ix) foreign currency transaction, net, and (x) sales discount reversals. We have included Adjusted EBITDA because it is a key measure used by our management team to evaluate our operating performance, generate future operating plans, and make strategic decisions. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management team and Board of Directors. In addition, it provides a useful measure for period-to-period comparisons of our business, as it removes the effect of certain non-cash expenses and non-recurring and extraordinary items. For investors to better evaluate the Company's performance and compare results across reporting periods, Cosmos Health provides a reconciliation of GAAP to non-GAAP financial measures. These adjustments exclude certain non-cash and non-recurring items, including stock-based compensation, non-cash interest expense, changes in the fair value of derivatives and convertible notes, gains or losses on digital assets, foreign currency transactions, sales discount reversals, and other non-operating or non-recurring items, as applicable and as further described above. The presentation of the Company's non-GAAP financial measures is not meant to be considered in isolation or as a substitute for the Company's financial results prepared in accordance with GAAP, and the Company's non-GAAP measures may be different from non-GAAP measures used by other companies. Adjusted EBITDA has limitations as a financial measure, should be considered as supplemental in nature, and is not meant as a substitute for the related financial information prepared in accordance with GAAP. Adjusted Net Income (Loss) We define Adjusted Net Income (Loss) as Adjusted EBITDA (see above) adding provision for income taxes and deducting interest expense. Adjusted Net Income (Loss) has limitations as a financial measure, should be considered as supplemental in nature, and is not meant as a substitute for the related financial information prepared in accordance with GAAP. Reconciliation of Non-GAAP MeasuresAdjusted Revenue, Adjusted Gross Profit, Adjusted EBITDA & Adjusted Net Income (Loss) The following table presents reconciliations of Adjusted Revenue, Adjusted Gross Profit, Adjusted EBITDA and Adjusted Net Income (Loss) to the most directly comparable GAAP financial measures for each of the periods indicated. CONDENSED CONSOLIDATED BALANCE SHEET DATA About Cosmos Health Inc. Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available atwww.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr,www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X. Forward-Looking Statements With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company's business, operations, and the economy in general; the Company's ability to successfully develop and commercialize its proprietary products and technologies; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties - many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us - as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC's website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements. Investor Relations Contact: BDG [email protected] SOURCE: Cosmos Health Inc. View the original press release on ACCESS Newswire

By Brad Sorensen, CFA NASDAQ: COSM READ THE FULL COSM RESEARCH REPORT The latest earnings release from Cosmos Health Inc (NASDAQ: COSM) marks a clear inflection point in the company’s trajectory, with the financial results reinforcing a narrative of accelerating growth, improving operating efficiency, and expanding strategic optionality. The company delivered its strongest annual performance to date, with revenue reaching a record $65.3 million, representing 20% year-over-year growth—an outcome driven by strength across all core operating segments, including contract manufacturing, pharmaceutical distribution, and proprietary nutraceutical brands. What stands out most in this report is not simply the top-line growth, but the sharp improvement in profitability metrics. Gross profit surged 83% to $7.9 million, significantly outpacing revenue growth and driving a meaningful expansion in gross margin to 12.1%. This margin expansion reflects a favorable shift in product mix toward higher-value offerings, particularly within the company’s contract manufacturing division and branded product portfolio. It also signals that Cosmos is beginning to benefit from operating leverage as scale increases—an important milestone for a company that has historically operated at thinner margins. Further reinforcing this operational progress is the substantial improvement in earnings efficiency. Adjusted loss per share narrowed by approximately 82% year-over-year, indicating that while the company is not yet profitable on a GAAP basis, it is moving decisively in that direction. This trend, combined with an improvement in adjusted EBITDA, suggests that the underlying business is becoming structurally more efficient. Equally important is the dramatic strengthening of the balance sheet. Cash increased nearly tenfold to roughly $3.5 million, providing the company with significantly greater financial flexibility. This liquidity improvement is further amplified by the establishment of a $300 million financing facility, which positions Cosmos to pursue growth initiatives, including expansion of its manufacturing footprint, continued product development, and the buildout of a digital asset treasury strategy. While unconventional, this capital strategy underscores management’s willingness to explore non-traditional avenues to enhance shareholder value and fund expansion. From an operational standpoint, the earnings release highlights increasing visibility and durability in revenue streams. The company has secured long-term contract manufacturing agreements covering more than 12 million units of various products, providing a foundation of recurring revenue and improved forecasting confidence. At the same time, continued expansion of its proprietary brands—particularly Sky Premium Life—along with growing international demand (evidenced by repeat purchase orders in markets like the UAE) signals strengthening brand equity and distribution reach. Looking ahead, the strategic pipeline adds another layer to the investment case. Cosmos is advancing a range of initiatives, including AI-driven drug repurposing efforts, patented oncology assets, and new nutraceutical launches such as Liv18, which we wrote about recently, targeting large and growing markets like liver health. These programs, while still developing, introduce potential high-margin revenue streams that could materially enhance the company’s long-term profile. Taken together, this earnings report presents a company that is transitioning from a fragmented healthcare distributor into a more integrated, higher-margin platform with multiple growth vectors. The combination of accelerating revenue, expanding margins, improving earnings quality, strengthened liquidity, and a broadening strategic pipeline suggests that Cosmos Health is building momentum across both its core operations and its future-facing initiatives. For investors, the key takeaway is that the underlying fundamentals are moving in the right direction, with early signs that scale and strategy are beginning to translate into tangible financial progress, and should take a look at COSM at the beginning stages of what looks like a long and sustained ramp up. SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.

Scaled contract manufacturing division, securing long-term agreements for over 12 million units Expanded Sky Premium Life portfolio by 60 SKUs and accelerated global expansion, securing purchase orders for over 300,000 units across new markets Advanced R&D pipeline, securing patented anticancer drugs, multiple AI-driven patent filings, and CCX0722 weight management product entering final development Secured $300 million financing facility to launch digital asset treasury strategy CEO Greg Siokas increased ownership by over 3.3 million shares, reinforcing deep insider conviction Strong momentum continues into 2026 with record growth across all core segments and continued U.S. expansion underway CHICAGO, IL / ACCESS Newswire / April 15, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today reported financial results for the full year ended December 31, 2025, delivering the strongest annual revenue performance in the Company's history. Full Year 2025 Financial Highlights Performance was marked by all-time high revenue, significant gross profit expansion, and margin improvement, driven by strong performance across core business segments, including scaling the contract manufacturing division at Cana Laboratories, increased volumes in the CosmoFarm wholesale distribution business supported by an expanded pharmacy network, solid sales growth through Decahedron in the United Kingdom, and the global expansion of proprietary brands, including Sky Premium Life and C-Scrub. Income Statement Revenue increased by 20% to $65.27 million in FY 2025, compared to $54.43 million in FY 2024, representing the highest annual revenue in Company history and reflecting strong performance across all core divisions. Gross profit increased by 83% to $7.90 million, compared to $4.31 million in FY 2024, driven by improved product mix, increased contribution from higher-margin divisions, and operational efficiencies. Gross margin expanded to 12.10%, compared to 7.92% in FY 2024, representing a 418-basis point improvement. Total operating expenses increased to $24.60 million, compared to $19.86 million in FY 2024, reflecting strategic investments in talent and new hires, including managerial, sales, and scientific personnel, corporate growth initiatives supporting global expansion, as well as extensive provisions for doubtful accounts. Excluding provisions for doubtful accounts and other non-cash items, operating expenses remained broadly in line with the prior year. Total other income (expense), net, was ($2.44 million) in FY 2025, compared to ($0.64 million) in FY 2024, largely reflecting non-cash items, including mark-to-market losses on digital assets, non-cash interest expense, and changes in the fair value of convertible notes. Net income (loss) was ($19.14 million), compared to ($16.18 million) in FY 2024. Adjusted EBITDA improved to ($3.36 million), compared to ($3.44 million) in FY 2024, driven by stronger gross profitability and adjustments for non-cash and non-recurring items. Adjusted net income (loss) was ($5.98 million), compared to ($4.45 million) in FY 2024, primarily reflecting higher costs associated with business expansion and growth initiatives. Net income (loss) per share improved significantly, with reported net loss per share of ($0.63) compared to ($1.17) in 2024, while adjusted net income (loss) per share improved to ($0.12) from ($0.65) in the prior year. Balance Sheet Cosmos Health maintained a robust financial foundation, expanding its asset base and enhancing liquidity. The Company ended the year with a solid cash position to support growth initiatives. Total assets increased to $65.48 million, compared to $54.31 million as of December 31, 2024, reflecting growth across core business segments and expanded operational scale, supported by the following key components: Property and equipment , net, totaled $10.58 million, largely reflecting the Company's wholly owned real estate assets, including CosmoFarm's logistics center and Cana Laboratories' manufacturing facilities. Cash and cash equivalents totaled $3.46 million, compared to $0.32 million as of December 31, 2024, a more than tenfold increase. Digital assets totaled $1.41 million, reflecting investments in Ethereum under the Company's treasury diversification strategy. Inventory increased to $5.78 million, compared to $4.36 million, supporting expanded commercial activity and anticipated demand. Accounts receivable increased to $22.07 million, compared to $14.71 million, reflecting increased business volumes and continued commercial expansion. Goodwill and intangible assets , net, totaled $7.57 million, representing investments in intellectual property, including acquired licenses for established pharmaceutical and nutraceutical products. Prepaid expenses and other current assets increased to $6.54 million, compared to $4.89 million, reflecting strategic supplier prepayments and operational investments supporting growth and supply chain efficiency. Total liabilities increased to $47.05 million, compared to $29.78 million, primarily reflecting higher accounts payable, increased working capital requirements, and expanded credit facilities supporting business growth. Stockholders' equity totaled $18.42 million, compared to $24.53 million as of December 31, 2024, with the decrease primarily reflecting extensive non-cash provisions for doubtful accounts. CEO Statement Greg Siokas, CEO of Cosmos Health, stated: "2025 was the year Cosmos Health proved its model. Not with promises - with numbers. We delivered $65.3 million in revenue - a new all-time record, up 20% year-over-year. More importantly, our gross profit nearly doubled, growing 83% to $7.9 million, while gross margin expanded 418 basis points to 12.1%. Our Adjusted EPS improved by 82%, from ($0.65) to ($0.12). These are not incremental improvements. This is the structural transformation of a healthcare platform that has been methodically built over the past several years to be vertically integrated, globally diversified, and increasingly high-margin. At Cana Laboratories, we secured long-term contract manufacturing agreements representing over 12 million units - providing meaningful revenue visibility and a platform for continued margin expansion. Sky Premium Life secured over 300,000 units in new purchase orders globally, with 60 new SKUs introduced, bringing our total portfolio to over 150 products. We also delivered record distribution volumes at CosmoFarm, driven by an expanded pharmacy network, and we entered the United States - the world's largest nutraceuticals market - with locally manufactured, clinically validated products. NOOR Collagen is already generating sales with a clear path to over $12 million in annualized revenue at approximately 75% gross margins. We made bold strategic moves. We activated a $300 million digital asset facility and initiated an Ethereum treasury strategy. We secured buy-out rights and exclusive licensing for two patented anticancer drugs valued at over $24.5 million, targeting prostate, ovarian, and colorectal cancers. We advanced multiple AI-driven patent filings through Cloudscreen, our proprietary drug repurposing platform, targeting multiple sclerosis, gliomas and hematologic malignancies, as well as allergic inflammation. We ended the year with $3.5 million in cash, more than ten times our year-end 2024 cash position. We also own real estate assets with a fair market value that we believe exceeds our current market capitalization, and we are actively evaluating strategic options to unlock that value for our shareholders. I personally increased my ownership by over 3.3 million shares in 2025. I do not do that as a formality. I do that because I believe - with full conviction - that the intrinsic value of Cosmos Health is a significant multiple of where this stock trades today. Our revenue is at a record. Our margins are expanding. Our U.S. business is ramping. Our pipeline is advancing. And we have only just begun to realize the potential of this platform. 2026 has started with strong momentum across all divisions, and we will provide updated guidance in the near term. To our shareholders: we hear you. We are executing for you. And the best chapters of this story are still ahead." 2025 Business Highlights R&D and Product Innovation Entered new nanotechnology R&D program to develop next-generation nutraceutical formulations with enhanced phytochemical efficacy Advanced CCX0722 weight management solution into final development phase Filed AI-driven patent application (Application Number N2039646) for allergic inflammation therapy Advanced oncology pipeline with two new AI-driven patent filings (Application Numbers: N2039647 and N2039645) for gliomas and hematologic malignancies Secured buy-out rights and exclusive licensing for two patented anticancer drugs for prostate, ovarian, and colorectal cancers valued at over $24.5 million Filed AI-driven patent application (Application Number N2039644) targeting multiple sclerosis Expanded Sky Premium Life nutraceutical portfolio with 60 new SKUs, increasing total offerings to over 150 products Manufacturing and Operations Expanded Cana Laboratories facility upgrade program to increase production capacity Signed five year contract manufacturing agreement with Pharmex for 1.5 million bottles of AMBITASOL antiseptic Signed contract manufacturing agreement with Medical Pharmaquality for 3 million MYCOFAGYL pessaries annually Secured 10-year contract manufacturing agreement with Provident Pharmaceuticals totaling 8 million packs Global Commercial Expansion United States: Commenced U.S. operations supported by local manufacturing capabilities Launched NOOR Collagen, projected to generate over $12 million in revenue within 12 months and deliver approximately 75% gross margins Sky Premium Life: Received follow up order from Pharmalink for 80,000 Sky Premium Life units in the UAE following sell out of the initial 130,000 unit order Launched Sky Premium Life in Albania through partnership with Pharma Cell, securing an initial $300,000 order Expanded Sky Premium Life into Kuwait through exclusive distribution agreement with Diyar United, securing an initial order exceeding 65,000 units Entered Oman through distribution agreement with Scientific Pharmacy for Sky Premium Life, including an initial purchase order of 42,000 units PCR Kits: Expanded partnership with Virax Biolabs for avian influenza PCR kits, securing exclusive distribution rights across Europe and the GCC Strategic and Financial Milestones Secured up to $300 million financing facility to launch digital asset treasury Initiated digital asset treasury strategy with $2 million Ethereum investment Launched strategic partnership with Prime Ledger to tokenize intellectual property assets and enhance treasury strategy Secured a €2.2 million bond loan from a European bank on competitive terms, with an option to upsize, to support growth initiatives. The bond carries an interest rate of 2.95% plus the applicable 6-month Euribor. Regained compliance with Nasdaq minimum bid price requirement CEO Greg Siokas acquired more than 3.3 million shares in 2025, reinforcing alignment with shareholders CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (*) See "Definitions of Non-GAAP Measures" and "Reconciliation of Non-GAAP Measures" sections herein for an explanation and reconciliations of non-GAAP measures used throughout this release. Definitions of Non-GAAP Measures We collect and analyse operating and financial data to evaluate the health of our business and assess our performance. In addition to Revenue, Income (Loss) from Operations and Net Income (Loss) under GAAP, we use: EBITDA, Adjusted EBITDA, and Adjusted Net Income (Loss). We have included these non-GAAP financial measures because they are key measures used by our management to evaluate our operating performance. Accordingly, we believe that these non-GAAP financial measures provide useful information to investors and others in understanding and evaluating our operating results in the same manner as our management team and Board of Directors. Therefore, these non-GAAP financial measures are presented here. Our calculation of these non-GAAP financial measures may differ from similarly titled non-GAAP measures, if any, reported by our peer companies. These non-GAAP financial measures should not be considered in isolation from, or as substitutes for, financial information prepared in accordance with GAAP. Adjusted EBITDA We define Adjusted EBITDA as income (loss) before income taxes, excluding (i) depreciation and amortization expense, (ii) interest (income) expense, net, (iii) non-cash interest expense, (iv) stock-based compensation, (v) non-recurring and extraordinary items, (vi) other (income) expense, net, (vii) gain (loss) on equity investments and extinguishment of debt, net, (viii) change in fair value of derivatives and convertible notes, (ix) gain (loss) on digital assets, (x) foreign currency transactions, net, (xi) provisions for doubtful accounts, (xii) other non-cash provisions, and (xiii) impairment charges. We have included Adjusted EBITDA because it is a key measure used by our management team to evaluate our operating performance, generate future operating plans, and make strategic decisions. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management team and Board of Directors. In addition, it provides a useful measure for period-to-period comparisons of our business, as it removes the effect of certain non-cash expenses and non-recurring and extraordinary items. For investors to better evaluate the Company's performance and compare results across reporting periods, Cosmos Health provides a reconciliation of GAAP to non-GAAP financial measures. These adjustments exclude certain non-cash and non-recurring items, including stock-based compensation, non-cash interest expense, provisions for doubtful accounts, changes in the fair value of derivatives and convertible notes, gains or losses on digital assets, foreign currency transactions, and other non-operating or non-recurring items, as applicable and as further described above. The presentation of the Company's non-GAAP financial measures is not meant to be considered in isolation or as a substitute for the Company's financial results prepared in accordance with GAAP, and the Company's non-GAAP measures may be different from non-GAAP measures used by other companies. Adjusted Net Income (Loss) We define Adjusted Net Income (Loss) as Adjusted EBITDA (see above) adding provision for income taxes and deducting interest expense. Adjusted Net Income (Loss) has limitations as a financial measure, should be considered as supplemental in nature, and is not meant as a substitute for the related financial information prepared in accordance with GAAP. Reconciliation of Non-GAAP Measures Adjusted EBITDA & Adjusted Net Income (Loss) The following table presents reconciliations of Adjusted EBITDA & Adjusted Net Income (Loss) to the most directly comparable GAAP financial measure for each of the periods indicated. CONDENSED CONSOLIDATED BALANCE SHEET DATA About Cosmos Health Inc. Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X. Forward-Looking Statements With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company's business, operations, and the economy in general; and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise. Investor Relations Contact: BDG Communications [email protected] SOURCE: Cosmos Health Inc. View the original press release on ACCESS Newswire

CHICAGO, IL / ACCESS Newswire / April 1, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that C-Scrub Wash 4%, manufactured by its wholly owned subsidiary Cana Laboratories S.A., has successfully completed testing under EN 12791:2016+A1:2017, the European standard for surgical hand disinfection. The independent study, conducted by Quality Assurance & Control Systems Ltd. (QACS), a Greece-based testing and certification laboratory specializing in microbiological and disinfectant efficacy studies, confirmed that C-Scrub Wash 4% demonstrated effective antimicrobial activity for surgical hand disinfection in accordance with EN 12791 requirements. The product is formulated with 4% Chlorhexidine Digluconate and is designed for use in healthcare and clinical environments requiring high standards of hygiene and infection prevention. EN 12791 is a widely recognized European benchmark for surgical hand antisepsis products and supports entry into hospital, surgical, and professional healthcare channels. The Company believes that successful completion of this study strengthens the clinical positioning of C-Scrub Wash 4% and opens additional commercial opportunities across international healthcare markets. This milestone comes as C-Scrub continues gaining traction across several key markets, including the United Kingdom, where Cosmos Health has recently announced expanding commercial availability and growing market presence. The Company believes the EN 12791 study completion further supports its strategy to expand the C-Scrub portfolio across both retail and institutional healthcare channels. The Company believes that this achievement further strengthens Cosmos Health's infection control portfolio, enhances the commercial positioning of the C-Scrub brand, and supports continued international growth. Greg Siokas, CEO of Cosmos Health, stated: "The successful completion of the EN 12791 study for C-Scrub Wash 4% represents an important milestone for Cosmos Health. As demand for infection control solutions continues to grow across key markets, this achievement enhances the clinical credibility of our C-Scrub portfolio and supports expansion into hospital, surgical, and institutional healthcare markets globally. By achieving technical parity with established industry benchmarks, we reduce barriers to entry, strengthen our competitive positioning, and support projected sales growth across key healthcare markets." C-Scrub Wash 4% is a powerful antiseptic skin cleanser formulated with 4% Chlorhexidine Digluconate, designed to deliver broad antimicrobial protection. The product offers reliable disinfectant properties to help reduce bacteria and support infection prevention, making it suitable for healthcare professionals and clinical environments requiring high standards of hygiene. About Cosmos Health Inc. Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Lifeﾮ, Mediterranationﾮ, bio-bebeﾮ, C-Septﾮ and C-Scrubﾮ. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X. Forward-Looking Statements With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company's business, operations, and the economy in general; and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise. Investor Relations Contact: BDG Communications [email protected] SOURCE: Cosmos Health Inc. View the original press release on ACCESS Newswire

Continues to deliver record revenue and improving operating metrics Significant expansion in the United States underway, with NOOR and other Sky Premium Life products expected to drive strong profitability supported by gross margins of approximately 75% NOOR Collagen alone is projected to generate more than $12 million in annualized revenue Strong growth expected ahead, driven by organic progress and M&A pipeline including a recent LOI to acquire an $11.5 million pharmacy distribution network Holds valuable non-core strategic real estate and digital assets with an estimated fair market value exceeding $18 million, providing meaningful balance sheet flexibility Evaluating potential monetization of non-core assets to support more efficient capital allocation accelerate strategic investments address the current valuation disconnect, including options such as share repurchases Recent geopolitical turmoil has had a negligible impact on the Company’s operations, with record-breaking growth continuing at a strong pace To issue guidance update following the release of fourth quarter and full-year 2025 results Analyst coverage initiated by Zacks Small-Cap Research with a valuation of $4.50 per share CHICAGO, March 19, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today provided a corporate update and announced that it intends to issue updated operational, strategic, and financial guidance following the release of its fourth quarter and full-year 2025 financial results. Record Operating Momentum Cosmos Health continues to deliver record revenue and gross profit while improving operating metrics, reflecting disciplined execution across all core divisions. Management believes the Company is progressing toward sustained profitability as revenue continues to grow, scale efficiencies crystallize, and margins improve. The war in the Middle East and recent geopolitical turmoil have had a negligible impact on the Company’s operations. The Company expects record-breaking growth to continue at a strong pace as it advances toward sustained profitability. Strong Growth Amid Significant U.S. Expansion & Partnerships with Leading Retailers Recent milestones include the continued global expansion of the Company’s proprietary brands. Sky Premium Life is growing across Europe and beyond. Importantly, the Company has recently entered the United States market with its NOOR and other Sky Premium Life products. All NOOR Sky Premium Life products sold in the United States are manufactured locally in GMP-certified, FDA-registered, and UL-audited U.S. facilities, underscoring the Company’s commitment to regulatory excellence and product integrity while mitigating tariff exposure and cross-border logistical risks. Cosmos Health anticipates strong gross margins of approximately 75% and significant cash flow generation from its Sky Premium Life U.S. operations. NOOR Collagen alone is projected to generate more than $12 million in annualized revenue, with additional growth expected as the Company introduces new products and expands its Sky Premium Life portfolio in the U.S. to meet strong consumer demand. C-Scrub is gaining commercial validation in the United Kingdom through expanded retail presence at Tesco, the UK’s largest retailer, and Superdrug, the UK’s second-largest beauty and health retailer. The Company’s contract manufacturing division continues to expand through new long-term agreements, while its wholesale logistics operations are serving increasing volumes across a growing pharmacy network. R&D at the Forefront of Innovation Cosmos Health continues to advance its R&D pipeline, further strengthened by the recent appointment of Dr. Dimitrios Iliopoulos, a globally recognized expert in AI-driven drug discovery and clinical-stage biotechnology, to its Advisory Board. The Company expects to provide updates regarding significant progress across several R&D initiatives following the finalization of certain anticipated transactions. M&A Pipeline On March 6, 2026, Cosmos Health entered into a Letter of Intent to acquire an extensive pharmacy distribution network from an established pharmaceutical company serving the Greek market for almost 40 years. The network currently generates approximately $11.5 million in annual gross revenue and serves a broad base of pharmacy customers, supplying both pharmaceutical and para-pharmaceutical products. In addition, the Company is actively evaluating a robust pipeline of acquisition opportunities designed to expand its distribution footprint, enhance operating scale, and drive profitability. Balance Sheet Flexibility: $18 Million in Non-Core Assets In addition to its core healthcare operating segments, the Company holds valuable non-core strategic assets that provide meaningful balance sheet flexibility. Among others, the Company owns real estate assets with an estimated fair market value of approximately $15 million and has also deployed $3.1 million into digital assets under its treasury strategy. Zacks Coverage Initiated with $4.50 Per Share Valuation Zacks Small-Cap Research initiated coverage on the Company with a valuation of $4.50 per share, according to a research report published on January 13, 2026. The report highlights Cosmos Health’s diversified revenue base, vertically integrated pharmaceutical and manufacturing operations, technology-driven initiatives, expansion into the U.S. market, and improving financial performance as key factors supporting its valuation. Capital Allocation Considerations Amid Valuation Disconnect At current trading levels, the Company’s shares trade at a significant discount to reported book value (stockholders’ equity), and management believes the Company’s market capitalization does not fully reflect the intrinsic value of its diversified asset base and strong operating performance. While management recognizes the long-term strategic value of its real estate and digital asset holdings, it is also evaluating potential monetization options, subject to market conditions, that could generate substantial capital to address the current valuation disconnect and support key corporate priorities, including acquisitions, technology investments, debt reduction, and returning capital to shareholders, including share repurchases. Greg Siokas, CEO of Cosmos Health, stated: "Our operating performance remains strong, with record revenue, improving profitability metrics, and an important expansion in the United States already underway with local manufacturing capabilities. At the same time, our balance sheet provides meaningful flexibility through a diversified asset base that includes non-core assets such as wholly owned real estate and digital holdings with a collective fair market value potentially exceeding $18 million. This represents a significant amount relative to our current market capitalization. To provide greater visibility and a clear roadmap for investors, we intend to issue updated guidance on our operational, strategic, and financial outlook following our FY 2025 results and outline the next phase of our strategic priorities designed to enhance long-term shareholder value. Given current valuation levels, we are also evaluating capital allocation alternatives, including share repurchases.” About Cosmos Health Inc. Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X. Forward-Looking Statements With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise. Investor Relations Contact: BDG Communications [email protected]

CHICAGO, May 15, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights Income Statement Cosmos Health delivered solid results in Q1 2025, highlighted by a significant increase in gross profit and positive performance on both an Adjusted EBITDA and Adjusted Net Income basis, reflecting a meaningful turnaround in bottom-line performance. Revenue for Q1 2025 was $13.71 million, a decrease of 5.98% from $14.58 million in Q1 2024, primarily reflecting the Company’s strategic shift toward higher-margin focus areas and a disciplined reduction of promotional-dependent activities. Gross profit increased by 53.70% to $2.05 million, up from $1.33 million in the prior-year period, driven by an improved product mix and operational leverage. Segment contributions were as follows: Wholesale logistics distribution: $1.18 million Owned nutraceuticals/pharmaceuticals and manufacturing: $0.87 million Gross margin expanded by 581 basis points to 14.95%, compared to 9.14% in Q1 2024, reflecting a greater focus on higher-margin segments, including contract manufacturing and proprietary brands, as well as operational synergies realized at Cana Laboratories. Total operating expenses declined by 9.05% to $2.88 million, compared to $3.17 million in Q1 2024, reflecting: 17.34% reduction in salaries and wages, driven by efficiency initiatives 83.78% decline in sales and marketing expenses, due to a strategic reduction in promotional spend 14.46% decrease in general and administrative expenses, adjusted for non-cash items Net loss narrowed by 56.17% to $0.82 million, down from $1.87 million in the prior-year period. The loss was primarily attributable to costs related to the Company’s Nasdaq U.S. listing. Return to Profitability On an adjusted basis, Cosmos Health delivered profitable results in both EBITDA and Net Income, driven by improved gross profitability and disciplined cost management. Adjusted EBITDA increased by 157.8% to $0.37 million, compared to a loss of $0.64 million in Q1 2024. Adjusted Net Income improved by 139.4% to $0.28 million, versus a loss of $0.71 million in the prior-year period. Key contributors to this performance were the Company’s wholesale logistics segment (CosmoFarm) and its owned nutraceutical and pharmaceutical products portfolio, including Sky Premium Life®, which delivered strong results. Balance Sheet Stockholders’ equity increased by $1.42 million, while the liabilities-to-assets ratio remained a modest 54.6%, reflecting continued financial discipline. Total assets increased by 5.3% to $57.2 million, up from $54.3 million as of December 31, 2024, reflecting a diversified asset base with enhanced liquidity, a strong inventory position, and a solid real estate and intellectual property portfolio. Total liabilities increased by 4.9% to $31.24 million as of March 31, 2025, up from $29.78 million at year-end 2024, primarily due to moderate increases in lines of credit and notes payable, while accounts payable and other current liabilities remained relatively stable. Total stockholders’ and mezzanine equity increased by 5.8% to $25.95 million as of March 31, 2025, up from $24.53 million as of December 31, 2024. Cash Flow Statement Operating cash burn improved by 94.5% year-over-year, decreasing by $3.22 million to negative $0.19 million in Q1 2025 from negative $3.41 million in Q1 2024, primarily driven by improved working capital management, stronger accounts receivable collections, and lower prepaid expense outflows. Management Commentary Greg Siokas, CEO of Cosmos Health, stated: “We are pleased with our strong first-quarter performance and the steady progress across multiple strategic areas. Gross profit and gross margins increased significantly, supported by an improved product mix and stronger operating leverage. Our continued focus on efficiency and disciplined cost management is yielding tangible results, as reflected in our return to profitability on both an Adjusted EBITDA and Adjusted Net Income basis. Importantly, we are approaching a key milestone, having substantially reduced our operating cash burn and moving closer to operational cash flow breakeven. Moreover, we ended the quarter with higher stockholders’ equity and improved liquidity, including an increased cash balance. Our balance sheet remains prudent, underpinned by modest leverage and a diversified asset base. Operationally, we continue to advance strategic initiatives across the group. Our R&D pipeline is evolving, with multiple projects underway, including our CCX0722 weight management solution which has entered its final development phase and is progressing toward launch. We are also scaling our high-margin contract manufacturing segment through new long-term agreements, while expanding the global footprint of Sky Premium Life, our flagship nutraceutical brand. In parallel, we are growing our C-Scrub antiseptics line, including continued progress in the lucrative UK market. Finally, I want to reaffirm my personal commitment to Cosmos. Since December 20, 2024, I have increased my personal shareholding by over 2.7 million shares, representing an investment of more than $1.3 million, which reflects my strong confidence in the Company’s strategy and long-term growth potential.” (*) See "Definitions of Non-GAAP Measures" and "Reconciliation of Non-GAAP Measures" sections herein for an explanation and reconciliations of non-GAAP measures used throughout this release. Definitions of Non-GAAP Measures We collect and analyze operating and financial data to evaluate the health of our business and assess our performance. In addition to Revenue, Income (Loss) from Operations and Net Income (Loss) under GAAP, we use: EBITDA, Adjusted EBITDA, and Adjusted Net Income (Loss). We have included these non-GAAP financial measures because they are key measures used by our management to evaluate our operating performance. Accordingly, we believe that these non-GAAP financial measures provide useful information to investors and others in understanding and evaluating our operating results in the same manner as our management team and Board of Directors. Our calculation of these non-GAAP financial measures may differ from similarly titled non-GAAP measures, if any, reported by our peer companies. These non-GAAP financial measures should not be considered in isolation from, or as substitutes for, financial information prepared in accordance with GAAP. Adjusted EBITDA We define Adjusted EBITDA as Income (Loss) before Income Taxes, excluding (i) depreciation and amortization expense, (ii) interest income (expense), (iii) non-cash interest expense, (iv) stock-based compensation expense, (v) non-recurring and extraordinary items (vi) other income (expense), net, (vii) gain (loss) on equity investments, net, (viii) gain on extinguishment of debt, (ix) change in fair value of derivative liability (x) foreign currency transaction, net, and (xi) prior years bad debt allowances. We have included Adjusted EBITDA because it is a key measure used by our management team to evaluate our operating performance, generate future operating plans, and make strategic decisions. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management team and Board of Directors. In addition, it provides a useful measure for period-to-period comparisons of our business, as it removes the effect of certain non-cash expenses and non-recurring and extraordinary items. Adjusted EBITDA has limitations as a financial measure, should be considered as supplemental in nature, and is not meant as a substitute for the related financial information prepared in accordance with GAAP. Adjusted Net Income (Loss) We define Adjusted Net Income (Loss) as Adjusted EBITDA (see above) adding provision for income taxes and deducting interest expense. Adjusted Net Income has limitations as a financial measure, should be considered as supplemental in nature, and is not meant as a substitute for the related financial information prepared in accordance with GAAP. Reconciliation of Non-GAAP Measures Adjusted EBITDA & Adjusted Net Income (Loss) The following table presents reconciliations of Adjusted EBITDA & Adjusted Net Income (Loss) to the most directly comparable GAAP financial measure for each of the periods indicated. About Cosmos Health Inc. Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X. Forward-Looking Statements With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Relations Contact: BDG Communications [email protected] +44 207 0971 653

CHICAGO, April 16, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today reported financial results for the full year ended December 31, 2024. Full Year 2024 Financial Highlights Income Statement: FY 2024 performance was marked by revenue growth, an increase in R&D investments, and a substantial reduction in operating expenses, while bottom-line results were impacted by the absence of non-recurring gains recognized in the prior year. Revenue increased by 2.0% to $54.43 million in FY 2024, from $53.38 million in the prior year, driven primarily by sustained organic growth and continued contributions from prior acquisitions. Gross margin was 7.92%, compared to 8.15% in FY 2023, reflecting a greater mix of revenue from the lower-margin logistics distribution segment. Total operating expenses declined by 24.16% to $19.86 million, compared to $26.18 million in FY 2023. This includes: 40.26% reduction in general and administrative expenses. 71% decrease in sales and marketing expenses, following a strategic reduction in promotional spend. Total other income, net, was a loss of $0.64 million in FY 2024, compared to income of $3.29 million in FY 2023. The year-over-year decline was primarily due to the absence of non-cash gains recognized in the prior year, including: $1.91 million gain on debt extinguishment. $1.44 million bargain purchase gain related to the acquisition of Cana Laboratories. Adjusted EBITDA was negative $3.73 million, compared to positive $0.06 million in FY 2023, while Adjusted net loss widened to $4.74 million from $0.81 million. Balance Sheet: The liabilities-to-assets ratio remains a modest 55% as of year-end 2024, reflecting a balanced capital structure and continued financial discipline. Total assets decreased by 17.72% to $54.31 million as of December 31, 2024, from $66.01 million at the end of 2023, while the Company continued to maintain a well-diversified asset base, supported by the following key components: Tangible asset base, with property and equipment, net, totaling $9.69 million, largely reflecting the Company’s wholly owned real estate assets, including CosmoFarm’s logistics center and Cana Laboratories’ manufacturing facilities. Goodwill and intangible assets, net, totaling $7.76 million, representing investments in intellectual property, including acquired licenses for established pharmaceutical and nutraceutical products. Inventory position of $4.36 million, reflecting enhanced procurement discipline and improved inventory management, with higher sales achieved despite a leaner inventory base. Total liabilities decreased by 0.64% to $29.78 million as of December 31, 2024, compared to $29.97 million at year-end 2023. Key highlights include: Operating lease liabilities declined by 41%, or $346,000, following the early termination of a long-term lease at the Thessaloniki corporate offices. This move supports the Company’s cost-efficiency strategy to consolidate all corporate functions in Athens. Accounts payable decreased by $754,000, or 6%, reflecting tighter cash flow management and more proactive settlement of supplier obligations. Total stockholders’ and mezzanine equity stood at $24.53 million, versus $36.04 million as of December 31, 2023. Recent Highlights R&D and Product Innovation Advanced the pipeline with AI-driven patent filings targeting multiple sclerosis, allergic inflammation, gliomas and hematologic malignancies. Entered the final development phase for CCX0722, a proprietary weight management solution, with product launch expected in 2026. Secured two WIPO-patented anticancer drugs for prostate, ovarian, and colorectal cancers, valued at over $24.5 million, enhancing the oncology portfolio. Strengthened leadership with the appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology. Manufacturing Expanded Cana Laboratories’ facilities and production capabilities. Signed long-term manufacturing contracts with Pharmex and Provident Pharmaceuticals, covering over 9.5 million units across multiple product lines, enhancing revenue visibility and supporting margin expansion. Global Commercial Expansion Expanded the Sky Premium Life nutraceutical brand with 60 new SKUs. Launched the Sky Premium Life brand in Albania, supported by a $300,000 initial order, and secured a $578,460 order in Qatar. Expanded distribution of avian influenza PCR kits across Europe and the GCC through an exclusive agreement with Virax Biolabs. Strategic & Financial Milestones Strengthened the executive team with the appointment of Dimitris Moraitis as Vice President of Strategy & Operations. Secured a €2.2 million (approximately $2.29 million) secured bond loan from a European bank on competitive terms, with an option to upsize. The bond carries an interest rate of 2.95% plus the applicable 6-month Euribor. CEO Greg Siokas acquired over 1 million common shares through multiple transactions between December 20, 2024, and March 4, 2025. Integrated Bitcoin and Ethereum as treasury reserve assets. Management Commentary Greg Siokas, CEO of Cosmos Health, stated: "We have achieved a number of important milestones over the past year, but I believe we are still in the very early stages of what represents a key inflection point for Cosmos. On the R&D front, we are leveraging AI-driven drug repurposing technologies to advance our research agenda, and our scientists are making meaningful progress toward the commercialization of our proprietary weight loss drug. In manufacturing, we continue to invest in our Cana Laboratories facility and are securing long-term contract manufacturing agreements, a strategic and high-margin segment for us. We are also investing in the development of our portfolio of proprietary brands, most notably through the rapid global expansion of Sky Premium Life, our high-margin nutraceutical line, which continues to grow with the addition of new SKUs and increasing market penetration across regions including Europe and the Middle East. As we’ve previously noted, our hard assets offer valuable strategic flexibility. We recently capitalized on this by securing a €2.2 million loan against our CosmoFarm logistics center on highly attractive terms. Importantly, this is a structure we can replicate, particularly with our significantly more valuable real estate at Cana Laboratories. Lastly, I continue to demonstrate my commitment to Cosmos. Since December 20, 2024, I have increased my personal ownership by over 1 million shares, a clear reflection of my confidence in the Company’s long-term strategy and future potential.” CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (*) See "Definitions of Non-GAAP Measures" and "Reconciliation of Non-GAAP Measures" sections herein for an explanation and reconciliations of non-GAAP measures used throughout this release. Definitions of Non-GAAP Measures We collect and analyze operating and financial data to evaluate the health of our business and assess our performance. In addition to Revenue, Income (Loss) from Operations and Net Income (Loss) under GAAP, we use: EBITDA, Adjusted EBITDA, and Adjusted Net Income (Loss). We have included these non-GAAP financial measures because they are key measures used by our management to evaluate our operating performance. Accordingly, we believe that these non-GAAP financial measures provide useful information to investors and others in understanding and evaluating our operating results in the same manner as our management team and Board of Directors. Our calculation of these non-GAAP financial measures may differ from similarly titled non-GAAP measures, if any, reported by our peer companies. These non-GAAP financial measures should not be considered in isolation from, or as substitutes for, financial information prepared in accordance with GAAP. Adjusted EBITDA We define Adjusted EBITDA as Income (Loss) before Income Taxes, excluding (i) depreciation and amortization expense, (ii) interest income (expense), (iii) non-cash interest expense, (iv) stock-based compensation expense, (v) non-recurring and extraordinary items (vi) other income (expense), net, (vii) gain (loss) on equity investments, net, (viii) gain on extinguishment of debt, (ix) change in fair value of derivative liability (x) foreign currency transaction, net, and (xi) prior years bad debt allowances. We have included Adjusted EBITDA because it is a key measure used by our management team to evaluate our operating performance, generate future operating plans, and make strategic decisions. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management team and Board of Directors. In addition, it provides a useful measure for period-to-period comparisons of our business, as it removes the effect of certain non-cash expenses and non-recurring and extraordinary items. Adjusted EBITDA has limitations as a financial measure, should be considered as supplemental in nature, and is not meant as a substitute for the related financial information prepared in accordance with GAAP. Adjusted Net Income (Loss) We define Adjusted Net Income (Loss) as Adjusted EBITDA (see above) adding provision for income taxes and deducting interest expense. Adjusted Net Income has limitations as a financial measure, should be considered as supplemental in nature, and is not meant as a substitute for the related financial information prepared in accordance with GAAP. Reconciliation of Non-GAAP Measures Adjusted EBITDA & Adjusted Net Income (Loss) The following table presents reconciliations of Adjusted EBITDA & Adjusted Net Income (Loss) to the most directly comparable GAAP financial measure for each of the periods indicated. CONDENSED CONSOLIDATED BALANCE SHEET DATA About Cosmos Health Inc. Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X. Forward-Looking StatementsWith the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Relations Contact:BDG [email protected]+44 207 0971 653